FDA Clearance Tracker · P120005-S011
DEXCOM G4 PLATINUM PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM
Last checked: Nov 20, 2026Latest source record: Jun 3, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Jun 3, 2014
Approved
Time to decision
260 days
Received Sep 16, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P120005-S011
- Device name
- DEXCOM G4 PLATINUM PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Sep 16, 2013
- Decided
- Jun 3, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P120005
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE G4 PLATINUM PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM, THAT INCLUDES THE DEXCOM G4 PLATINUM PROFESSIONAL RECEIVER SHIELD, TO ALLOW MULTIPLE PATIENT USE OF THE SYSTEM BY A HEALTHCARE PROFESSIONAL. THE DEVICE, AS MODIFIED, WILL BE MARKETEDUNDER THE TRADE NAME G4 PLATINUM PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM AND IS INDICATED FOR:THE DEXCOM G4 PLATINUM PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM IS A GLUCOSE MONITORING DEVICE INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN PERSONS (AGE 18 AND OLDER) WITH DIABETES. THE SYSTEM IS INTENDED FOR MULTIPLE PATIENT USE AND REQUIRES PURCHASE BY A HEALTHCARE PROVIDER. THE SYSTEM IS NOT INTENDED FOR USE IN A HOSPITAL SETTING.THE DEXCOM G4 PLATINUM PROFESSIONAL SYSTEM IS INDICATED FOR USE AS AN ADJUNCTIVE DEVICE TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES.THE DEXCOM G4 PLATINUM PROFESSIONAL SYSTEM AIDS IN THE DETECTION OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF THE G4 PLATINUM PROFESSIONAL SYSTEM RESULTS SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERALSEQUENTIAL READINGS OVER TIME.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.